Novel neurosteroid therapeutics for post-partum depression: perspectives on clinical trials, program development, active research, and future directions.

ABSTRACT: This article reviews novel neurosteroid therapeutics for post-partum depression, with a focus on their development, clinical trial data, current practices, and future directions in this exciting field. We discuss the clinical impact of brexanolone and several other neurosteroids, particularly as they relate to the treatment of postpartum depression (PPD) and major depressive disorders outside of the perinatal period. There has been increasing interest in GABA signaling and modulation as it pertains to the development of altered circuity and depressive states. This scientific underpinning served as the rationale for the initial development of brexanolone. We review the clinical trials supporting its Food and Drug Administration (FDA) approval as the first rapidly acting antidepressant speci

SUBMITTER: Patterson R 

PROVIDER: S-EPMC10700474 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature